Cases & Deals

  • Home
  • Practices
  • Royalty Pharma and Biohaven Pharmaceutical enter into rimegepant (BHV-3000) royalty agreement

Share

Royalty Pharma and Biohaven Pharmaceutical enter into rimegepant (BHV-3000) royalty agreement

June 2018

Client(s) RP Management LLC

Jones Day advised Royalty Pharma in the acquisition of Biohaven Pharmaceutical Holding Company Ltd.'s approximately 2% royalty rights in Biohaven’s rimegepant (BHV-3000) and BHV- 3500 (vazegepant) for an upfront cash payment of $100 million.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.